NCT04499469

Brief Summary

Nasal obstruction is one of the majors concerns in reduction rhinoseptoplasty, because it affects quality of life and surgical outcomes. Is the association of middle third grafts with reduction rhinoseptoplasty responsible for an increase in quality of life related to nasal obstruction when compared to reduction rhinoseptoplasty without the placement of these grafts?

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 3, 2018

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

July 21, 2020

Completed
15 days until next milestone

First Posted

Study publicly available on registry

August 5, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

August 5, 2020

Status Verified

July 1, 2020

Enrollment Period

2.4 years

First QC Date

July 21, 2020

Last Update Submit

July 31, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Nasal Obstruction Symptom Evaluation Scale (NOSE)

    The NOSE will be used to measure the quality of life related to nasal obstruction. It is a validated instrument specifically designed for use in patients with nasal obstruction. According to this scale patients are asked to evaluate difficulty breathing in a general way and specifically the difficulty in breathing through the nose, breathing during sleep, and severity of their nasal congestion. The severity of the symptoms is recorded on a scale of 0 to 4, with 0 being the absence of a problem and 4 being a serious problem. The possible scores range from 0 to 20 and the higher scores indicate a higher degree of nasal obstruction. The sum of the scores is multiplied by 5 so as to obtain a final score ranging from 0 to 100, with higher values associated with poorer quality of life. The scale will be applied at the base line and at 30, 90 and 180 postoperative days.

    180 postoperative days

Secondary Outcomes (5)

  • Rhinoplasty Outcome Evaluation (ROE) Scale

    180 postoperative days

  • Visual Analogue Scale - Nasal Obstruction

    180 postoperative days

  • Clinical Diagnosis of Allergic Rhinitis

    Base line and 180 postoperative days

  • Complications

    7 until 180 postoperative days

  • Anterior Rhinoscopy and Nasal Endoscopy

    Base line and 180 postoperative days

Study Arms (2)

Spreader Graft

EXPERIMENTAL

Placement and attachment with 5.0 polydioxanone (PDS) suture 2 grafts in the middle third of the nose

Procedure: Spreader Graft

Without Spreader Graft

NO INTERVENTION

No engraftment in the middle third

Interventions

To place and attach with 5.0 PDS suture 2 grafts in the middle third of the nose

Also known as: Middle Third Grafts
Spreader Graft

Eligibility Criteria

Age14 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may not qualify if:

  • Absence of nasal obstruction;
  • Previous nasosinusal surgery;
  • Symmetrical or asymmetric insufficiency of the middle third that would justify the placement of middle third grafts for the treatment of these problems;
  • Presence of nasal valve insufficiency as the only cause of nasal obstruction;
  • Cranio-facial anomalies;
  • Presence of nasosinusal tumors;
  • Active acute rhinosinusitis;
  • Patients undergoing treatment of other entities concomitant to rhinoseptoplasty such as: sinus inflammatory surgery, adenoid hypertrophy removal, septal perforation correction, otoplasty or blepharoplasty.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Raphaella Migliavacca

Porto Alegre, Rio Grande do Sul, 90480030, Brazil

RECRUITING

MeSH Terms

Conditions

Nasal Obstruction

Condition Hierarchy (Ancestors)

Nose DiseasesRespiratory Tract DiseasesAirway ObstructionRespiratory InsufficiencyRespiration DisordersOtorhinolaryngologic Diseases

Study Officials

  • Michelle Lavinsky-Wolff, PhD

    Federal University of Health Science of Porto Alegre

    STUDY DIRECTOR

Central Study Contacts

Michelle Lavinsky-Wolff, PhD

CONTACT

Raphaella Migliavacca, MsC

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2020

First Posted

August 5, 2020

Study Start

October 3, 2018

Primary Completion

March 1, 2021

Study Completion

June 1, 2021

Last Updated

August 5, 2020

Record last verified: 2020-07

Locations